Kazia Therapeutics (KZIA) Stock
Kazia Therapeutics (KZIA) closed at $5.37 on Nov 19, 2026; its Tenet Score is 50 of 100 against 486 Healthcare peers.
Key stats
- Close
- $5.37
- Nov 19, 2026
- Market cap
- $68.2Munverified basis
- share basis not confirmed
- Dividend yield
- 57.70%
- past year's regular dividends ÷ price
- 52-week range
- 4.86 – 17.40
- low → high
- Tenet Score
- 50/100
- Mixed · 486 Healthcare peers
Industry: Drugs · see every company filed here →
Kazia Therapeutics Limited scores 50/100. Mixed. Strongest on growth, quality is the soft spot versus 486 Healthcare peers. Insufficient inputs: Tenet 50 is built from 3 of 4 pillars, from 40% of its inputs. The pillars showing a dash had no data.
Tenet Score · vs sector
n=486Factor grades
Value omitted — no data yet.
Price
Market cap: share price × the latest quarter's diluted weighted-average share count (vendor).
The whole report, at a glance · every card is a live peek, click any to open the section
- ✕ Buffett Quality
- ✕ Piotroski F-Score
- ✕ Graham Defensive
- ✕ Quality Compounder
- ✕ Drawdown Context
- ✕ Reversal Evidence
Pays 57.70%. Yield is one component of total return.
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential thera…
Common questions
What sector and industry is Kazia Therapeutics in?
Kazia Therapeutics is in the Healthcare sector and the Drugs industry.
What is Kazia Therapeutics' Tenet Score?
Kazia Therapeutics' Tenet Score is 50 out of 100, ranked against 486 Healthcare peers as of Nov 20, 2026.




